Pharmacologic therapy of dementia with Lewy bodies

Journal of Geriatric Psychiatry and Neurology

Volumn 15, Issue 4, 2002, Pages 224-232

  Kaufer, Daniel I ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FLUOXETINE; GALANTAMINE; HALOPERIDOL; LEVODOPA; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERGOLIDE; PERGOLIDE MESILATE; PHYSOSTIGMINE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANOREXIA; ANTICHOLINERGIC EFFECT; BRADYKINESIA; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; DEMENTIA; DOPAMINERGIC SYSTEM; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSALIVATION; LEWY BODY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RIGIDITY; SIDE EFFECT; SOMNOLENCE; VERTIGO; VOMITING;

EID: 0036894381     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198870201500408     Document Type: Review

References (58)

1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report on the Consortium on DLB International Workshop. Neurology 1996; 47:1113-1124.
2. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: A clinical and pathological entity. Neurology 1990; 40:1-8.
3. Saghal A, Galloway PH, McKeith IG, et al. A comparative study of attentional deficits in senile dementias of Alzheimer and Lewy body types. Dementia 1992; 3:350-354.
4. Calderon J, Perry RJ, Erzinclioglu SW, et al. Perception, attention, and memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70:157-164.
5. McKeith IG, Perry RH, Fairbairn AF, et al. Operational criteria for senile dementia of the Lewy body type (SDLT). Psychol Med 1992; 22:911-922.
6. Samuel W, Henderson VE, Miller CE. Severity of dementia in Alzheimer's disease and neurofibrillary tangles in multiple brain regions. Alzheimer Dis Assoc Disord 1991; 5:1-11.
7. Samuel W, Alford M, Hofstetter CR, Hansen L. Dementia with Lewy bodies versus pure Alzheimer's disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997; 56:499-508.
8. Stern Y, Jacobs D, Goldman J, et al. An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol 2001; 58:460-465.
9. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54:1916-1921.
10. Langlais PJ, Thal LJ, Hansen L, et al. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993; 43:1927-1934.
11. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7:69-79.
12. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54:407-411.
13. Jellinger K, Bancher C, Fischer P. Neuropathological correlates of mental dysfunction in Parkinson's disease. In: Wolters C, Scheltens E, eds. Mental Dysfunction in Parkinson's Disease. Amsterdam: Vrije Univeriteit, 1993:141-161.
14. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22:273-280.
15. Dringenberg HC. Alzheimer's disease: More than a 'cholinergic disorder' - Evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 2000; 115:235-249.
16. Briel RC, McKeith IG, Barker WA, et al. EEG findings in dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999; 66:401-403.
17. Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999; 156:1039-1045.
18. Simard M, van Reekum R, Cohen T. A review of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2000; 12:425-450.
19. Perry EK, Marshall E, Kerwin JM, et al. Evidence of a monoaminergic cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990; 55:1454-1456.
20. McShane R, Keene J, Gedling K, et al. Hallucinations, cortical Lewy body pathology, cognitive function, and neuroleptic use in dementia. In: Perry RH, McKeith IG, Perry EK, eds. Dementia with Lewy Bodies: Clinical, Pathological, and Treatment Issues. New York: Cambridge University Press, 1996:85-98.
21. Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2000; 56:643-649.
22. Minoshima S, Foster NL, Sima AAF, et al. Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50:358-365.
23. Gnanalingham K, Byrne E, Thornton A, et al. Motor and cognitive function in Lewy body dementia; comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997; 62:243-252.
24. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: A clinicopoathological study of 35 cases. Clin Neuropathol 1989; 7:299-305.
25. Walker Z, Costa DC, Ince P, et al. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet 1999; 354:646-647.
26. Grace JB, Walker MP, McKeith IG. A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000; 11:1028-1033.
27. Turner RS. Idiopathic rapid eye movement sleep behavior disorder is a harbinger of dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2002; 15:195-199.
28. Wennings GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: A clinicopathological study. J Neurol Neurosurg Psychiatry 1999; 67:620-623.
29. Lingler JH, Kaufer DI. Cognitive and motor symptoms in dementia: Focus on dementia with Lewy bodies. J Am Acad Nurse Pract 2002; in press.
30. McKeith IG, Fairbairn A, Perry RH, et al, Neuroleptic sensitivity in patients with senile dementia of the Lewy body type. BMJ 1992; 305:673-678.
31. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999; 66:137-147.
32. Lawrence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheimer's disease: Focus on cholinergic systems. Neurochem Res 1998; 23:787-794.
33. Cummings JL, Kaufer DI. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996; 47:876-883.
34. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993; 33:536-541.
35. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996; 9:1-6.
36. Kaufer DI, Catt KE, Lopez OL, DeKosky ST. Dementia with Lewy bodies: Response of delirium-like features to donepezil. Neurology 1998; 51:1512.
37. Aarsland D, Bronnick K, Karlsen K. Donepezil for dementia with Lewy bodies: A case study. Int J Geriatr Psychiatry 1999; 14:69-72.
38. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients. Int Psychogeriatr 1998; 3:229-238.
39. McKeith IG, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036.
40. Physician's Desk Reference. Montvale, NJ: Medical Economics, 2001.
41. Cummings JL. Cholinesterase-inhibitors: A new class of psychotropic compounds. Am J Psychiatry 2000; 157:4-15.
42. Reminyl [Package Insert]. Titusville, NJ: Janssen Pharmaceutica Products LP, 2001.
43. Newhouse PA, Potter A, Levin ED, et al. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Drugs Aging 1997; 11:206-228.
44. Knapp MJ, Knopman DS, Solomon PR, and the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991.
45. Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:292-303.
46. Corey-Bloom J, Anand R, Veach J, for the ENA-713 (rivistigmine tartrate) B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA-713, a new cholinesterase-inhibitor in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 1998; 1:55-65.
47. Raskind MA, Peskind ER, Wessel T, Yuan W, for the Galantamine USA-1 Study Group. Galantamine in AD: A six-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54:2261-2268.
48. Ballard CG, Grace J, McKeith IG, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998; 351:1032-1033.
49. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 1999; 60:107-115.
50. De Duyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:946-955.
51. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995; 346:185.
52. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Am J Psychiatry 2000; 57:968-976.
53. Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: A clinical study. Int J Geriatr Psychiatry 1999; 14:459-466.
54. McManus DQ, Arvantis LA, Kowalcyk BB, et al. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999; 60:292-298.
55. Campbell S, Stephens S, Ballard C. Dementia with Lewy bodies: Clinical features and treatment. Drugs Aging 2001; 18:397-407.
56. Louis ED, Klatka LA, Liu Y, et al. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997; 48:376-380.
57. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: A report of three cases. Neurology 2000; 55:870-871.
58. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson's disease. Drugs Aging 2001; 18:495-505.